drugset / Trial / NCT02279719
A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open label, three-arm, phase 1 dose escalation study and phase 2 study of BBI608 in combination with sorafenib, or BBI503 in combination with sorafenib. The study population is adult patients with advanced hepatocellular carcinoma who have not received systemic chemotherapy.
Timeline
- Start
- 2014-12
- Primary completion
- 2019-07
- Completion
- 2019-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMCASERTIB | Small molecule | — | — |
| Subject | Napabucasin | Small molecule | — | — |
| Background | Sorafenib | Small molecule | 400 mg | — |